QualityStocks.net News – AVANIR Pharmaceuticals (AVNR) Receives European Patent Approval for Extended Commercial Exclusivity for Zenair

At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.

We would like to highlight AVANIR Pharmaceuticals (AVNR). The Company acquires, develops and commercializes therapeutic products for the treatment of chronic diseases of the central nervous system, as well as inflammatory and infectious diseases.

In the company’s recent news,

AVANIR Pharmaceuticals announced the European patent office has granted the company a new patent, which extends the exclusivity period for its lead product candidate, Zenvia - used in the treatment of pseudobulbar affect (PBA) - through 2023. The new European patent fits well into the company’s objectives, encompassing the company’s current clinical development programs in PBA and diabetic peripheral neuropathic (DPN) pain, as well as other neurologic conditions.

PBA is a disinhibition syndrome associated with various neuropathologies, and is characterized by involuntary, and sometimes inappropriate, outbursts of laughter or crying. But it’s no laughing matter; PBA is oftentimes referred to as “pathological laughing and weeping”, “emotional liability”, or “pathologic emotionality”, and is associated with multiple sclerosis, Alzheimer’s disease, strokes and other conditions. Receiving the patent will allow the company to further pursue its developments and commercial exclusivity to treat PBA.

“The granting of a new European patent for Zenvia is another important milestone for AVANIR,” Keith Katkin, AVANIR’s president and CEO stated in a press release. “Our entire team is working diligently to complete the phase 3 clinical development of Zenvia for the PBA indication and prepare for our expected commercialization in the U.S. This new patent significantly extends the period of Zenvia commercial exclusivity throughout Europe and enhances the global potential of our primary asset.”

“We are extremely pleased with the decision by the European Patent Office to grant this application. This patent provides a significantly longer period of commercial exclusivity for Zenvia in Europe, and adds to AVANIR’s broad intellectual property portfolio,” Greg Flesher, vice president of business development at AVANIR stated in the press release. “We have the corresponding patent application pending within the U.S. Patent and Trademark Office, and based on the issuance of the European patent we are optimistic about receiving a similar response in the U.S. as well.”

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.